Navigation Links
Access Pharmaceuticals Provides Update on ProLindac(TM)Clinical Development Plan
Date:9/10/2009

imaging.cancer.gov/clinicaltrials/imaging/" target="_new">RECIST criteria. No patient in any dose group exhibited any signs of acute neurotoxicity, which is a major adverse side-effect of the approved DACH platinum, Eloxatin, and ProLindac was well tolerated overall.

The recent Phase 2 recurrent ovarian study explored three different dose levels and two dosing regimens of ProLindac as a monotherapy treatment for advanced ovarian cancer, to provide data on the monotherapy anticancer activity and safety of ProLindac. Of patients eligible for evaluation according to standard RECIST criteria, clinically-meaningful disease stabilization was achieved in 42% of all patients, and 66% of all patients in the higher dose groups. Sustained and significant reductions in Ca-125, the established specific serum marker for ovarian cancer, were also observed in several patients.

"Access is extremely pleased with the clinical progress to date, and look forward to initiation of clinical trials looking at ProLindac in combination with commonly used chemotherapies," stated Jeffrey Davis, President & CEO. "Our partners in the Far East hosted Access together with key opinion leaders in oncology indications to discuss various potential protocol options, and hope to start enrolling patients in up to three combination trials by the end of the year, depending upon regulatory approvals of the trial protocols and certain other matters."

About ProLindac(TM):

ProLindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes that ProLindac's unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin, which has sales in excess of $2 billion.
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Healthcare Conference
2. NuAire Laboratory Economic Stimulus Package -- Free Accessories or Factory Options
3. One of the Nation's Leading Analytical Testing Laboratories is Now Easier to Access -- Pace Analytical Launches New Web Site to Showcase Its Three Business Divisions
4. Understanding Managed Markets: Effective Market Research Structures & Activities to Maximize Payer Access & Insights
5. Access Pharmaceuticals CEO Interviewed on Financial Website
6. Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)
7. FDA Clears Boston Scientifics SpyScope(R) Access and Delivery Catheter for Use in Endoscopic Procedures Throughout Pancreatico-Biliary System
8. Reorganizational Healing Provides Access to Greater Quality of Life, Reduced Stress
9. Solvay Pharmaceuticals Announces Strategic Partnership With HUYA to Access new Drug Candidates From China
10. Cyprotex Launches Cloe(R) Gateway, its Secure web Portal for Access to Cyprotex Services Including an Enhanced Version of Cloe(R) PK.
11. Ochsner and LSUHSC Partner to Provide Better Local Access to Comprehensive Cancer Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 2015 Spirax Sarco, the leader ... their newly designed, state-of-the-art website in the first ... effectively promotes the Spirax Sarco brand, company capabilities, ... that a site visitor might be looking for ... industries serviced, the latest company news, careers, and ...
(Date:4/16/2015)... CA (PRWEB) April 16, 2015 Cytokinetics, ... to report first quarter results on Thursday, April 30, ... Cytokinetics’ senior management will host a conference call at ... results and the company’s outlook for the future. , ... be accessed from the homepage and in the Investor ...
(Date:4/16/2015)... , April 16, 2015  Schulman Associates IRB, Inc., ... has signed a long-term lease on Laboratory Drive in ... Carolina . The location will house review board ... provide high quality reviews and customer service to clients. ... represented Schulman in the deal, while Capital Associates ...
(Date:4/16/2015)... CHARLOTTE, N.C. (PRWEB) April 16, 2015 ... North Carolina at Charlotte (UNC Charlotte) spin-out company, ... David L. Cooper, Ph.D., M.D., as Chief Operating ... 20 years of experience in developing clinical diagnostic ... oncology and infectious disease. , Cooper’s extensive career ...
Breaking Biology Technology:Spirax Sarco website has a new look 2Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3Schulman IRB to Open Office in Research Triangle Park, N.C. 2OncoTAb Names Dr. David L. Cooper as COO 2
... - TOPIC: The state of the microRNA market and the ... current and potential impact on drug discovery, molecular, ... Tuesday, March 31, 2009, - TIME: ... - HOST: Christi Bird, Senior Research Analyst, Healthcare, ...
... March 30 BioVex Inc, a company developing new ... and infectious disease, announced today it has raised $40 ... private financing.The placement was led by Forbion Capital Partners, ... Agricole Private Equity, Harris & Harris Group, Innoven Partners, ...
... software for clinical research trials has named Jovianna DiCarlo President ... years experience driving new pharmaceutical therapeutics and devices through the ... to commercialization. , ... Frederick, MD ...
Cached Biology Technology:Frost & Sullivan Hosts Presentation on MicroRNAs: From Stem Cells and Cancer to Diagnostics and Therapeutics 2BioVex Raises $40 Million in First Close of Series F Financing 2BioVex Raises $40 Million in First Close of Series F Financing 3Jovianna DiCarlo Named ConsentSolutions, Inc. President & Chief Executive Officer 2
(Date:4/14/2015)... NEW YORK , April 14, 2015 /PRNewswire/ ... Fast IDentity Online (FIDO ® ) Alliance tm ... standards-based specifications. FIDO members commit to share technology ... authentication methods that are interoperable, more secure and ... specifications enable biometric identity verification that protects sensitive ...
(Date:4/13/2015)... YORK , April 13, 2015 ... by TechSci Research, "Global Biometrics Market Forecast & Opportunities, ... register a CAGR of around 14% till 2020. ... governments for large scale implementation and review of ... and launch of new products with greater efficiency, ...
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... inside each cell, a little engine called RNA polymerase II ... the nucleus that get carried to production units in the ... researchers at the University of Michigan Medical School have shown ... for damage. When certain types of damage in DNA halt ...
... LAFAYETTE, Ind. - A biomedical engineer at Purdue University ... that promises to be more effective than standard CPR ... by 25 percent over the current method. A ... a success rate of 5 percent to 10 percent, ...
... (09/05/07)--It is well established that a child,s brain has ... the extent to which such plasticity exists in the ... and Johns Hopkins University have used converging evidence from ... adult visual cortex does indeed reorganize-and that the change ...
Cached Biology News:Enzyme alerts cell's powerful army to repair DNA damage 2Enzyme alerts cell's powerful army to repair DNA damage 3New CPR promises better results by compressing abdomen, not Chest 2New CPR promises better results by compressing abdomen, not Chest 3New CPR promises better results by compressing abdomen, not Chest 4Adult brain can change, study confirms 2
...
... This monoclonal antibody recognizes 30% ... unrelated individuals. It does not ... proteins lacking rheumatoid factor nor with ... be used in ELISA to detect ...
...
Human VEGF R2 (KDR) MAb (Clone 89106)...
Biology Products: